The Use of Telmisartan and the Incidence of Cancer #MMPMID27557862
Tascilar K; Azoulay L; Dell?Aniello S; Bartels DB; Suissa S
Am J Hypertens 2016[Dec]; 29 (12): 1358-65 PMID27557862show ga
BACKGROUND: A meta-analysis reported an 8% increased risk of cancer with the use of angiotensin receptor blockers (ARBs), but subsequent meta-analyses and observational studies did not confirm this risk. However, telmisartan comprised 85% of the data in the original meta-analysis. Thus, the objective of this study was to determine whether the use of telmisartan, compared with other ARBs, is associated with an increased risk of cancer. METHODS: We used the United Kingdom Clinical Practice Research Datalink to assemble a cohort of all patients newly treated with ARBs between 2000 and 2008, and followed until December 2010. Time-dependent cox proportional hazards models were used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) of cancer associated with telmisartan, compared with other ARBs, adjusted for potential confounders. Secondary analyses assessed the risk with each of the 4 most common cancers (lung, breast, prostate, colorectal). RESULTS: The cohort consisted of 62,109 new ARB users, which included 3,438 telmisartan and 58,671 other ARB users. Compared with other ARBs, telmisartan use was not associated with an increased risk of cancer overall (16.3 vs. 15.0 per 1,000 person-years, respectively; adjusted HR: 0.93, 95% CI: 0.81?1.06) or by cancer site (lung, HR: 0.91, 95% CI: 0.55?1.51; breast, HR: 1.28, 95% CI: 0.90?1.82; prostate, HR: 0.79, 95% CI: 0.53?1.18; colorectal, HR: 1.41, 95% CI 0.95?2.10). CONCLUSIONS: Compared with other ARBs, telmisartan is not associated with an increased risk of cancer. This study provides reassurance as to the short-term safety of telmisartan.
free
free
free
Am+J+Hypertens 2016 ; 29 (12): 1358-65
